- Home
- TD vs NVO Comparison
TD vs NVO Comparison
Compare TD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TD | NVO |
|---|---|---|
| Founded | 1855 | 1923 |
| Country | Canada | Denmark |
| Employees | 70000 | 69500 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8B | 166.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TD | NVO |
|---|---|---|
| Price | $105.33 | $40.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | ★ $120.00 | $51.00 |
| AVG Volume (30 Days) | 2.6M | ★ 13.7M |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | 2.96% | ★ 3.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.48 | $3.88 |
| P/E Ratio | ★ $11.65 | $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.47 | $35.12 |
| 52 Week High | $104.44 | $81.44 |
Technical Indicators
Market Signals| Indicator | TD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 76.84 | 59.77 |
| Support Level | $92.13 | $35.49 |
| Resistance Level | N/A | $50.30 |
| Average True Range (ATR) | 1.39 | 1.01 |
| MACD | 1.07 | 0.79 |
| Stochastic Oscillator | 97.38 | 85.93 |
Price Performance
Historical ComparisonAbout TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.